Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
about
Pharmacogenetics in chronic heart failure: new developments and current challengesPharmacogenetics and anaesthesia: the value of genetic profilingPharmacogenomics and cardiovascular diseaseG protein-coupled receptors in cardiac biology: old and new receptorsThe Genetic Challenges and Opportunities in Advanced Heart FailureApplied pharmacogenomics in cardiovascular medicineβ1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosisBeta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases.Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directionsThe genomic architecture of sporadic heart failurePharmacogenomics in heart failure: where are we now and how can we reach clinical application?A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation.Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise.A case for pharmacogenomics in management of cardiac arrhythmias.Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) studyAdrenergic nervous system in heart failure: pathophysiology and therapy.Clinical and genetic modifiers of long-term survival in heart failure.Pharmacogenetics in heart failure: promises and challenges.Adrenergic signaling polymorphisms and their impact on cardiovascular disease.Heart failure pharmacogenetics: past, present, and future.Future of personalized pharmacotherapy in chronic heart failure patients.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Clinical considerations of heritable factors in common heart failureGenetic determinants of response to cardiovascular drugs.The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Genetic prediction of heart failure incidence, prognosis and beta-blocker response.Towards Precision in HF Pharmacotherapy.Pharmacogenomics of heart failure: a systematic review.Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background.The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart.Functional effects of β₁-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without β-blocker administration.Germline genetic variants with implications for disease risk and therapeutic outcomes.
P2860
Q26852239-96DB1176-6832-492F-9A7A-92FA8BF1649AQ26859221-39F24DAB-6C71-40DD-8825-6D73CC66E856Q26997380-CAD8800E-CFDE-41BC-8DC6-18C4CB2AE582Q33639685-9931EEE1-AD49-4029-B987-2FBDE6922177Q33653498-C83721F7-2AC1-433E-BCF5-2ED02F2687A3Q33846255-C9D313A9-CACD-49DC-9D3D-2C126B57B803Q34344600-69089261-4161-4828-8227-010ED5006267Q34658477-436B2BDD-4336-4513-A39B-B434E07900B9Q35033003-7CE81617-2DA3-419E-806A-30CB5F405450Q35033305-C47FC9AE-95EA-4ADE-8B4C-A365561F73FEQ35086882-3A6F7F8E-74D3-47BA-8E64-A5802668AFC8Q35633271-E45A99A1-5E3A-45E0-906D-302FC277C7C8Q35658737-8AAD7D3F-2004-45EF-A2E3-2A62B5985B98Q35914690-AD0BE689-0D70-43E2-8C59-D688DAE78246Q36638124-9D2E8D32-0A12-4DA0-82FB-9C0B151117B5Q37349756-665BF0D4-CA10-49C2-9101-29A22B8868B2Q37358823-610DA9C4-35A8-45E5-8E46-B03D195A1C6EQ37532571-FDCAB65E-4C87-4780-85E0-B7D5311EC702Q37776088-0FCFF64C-DAE9-4557-825D-02B55C7D66ABQ37854508-03E8D6F3-C286-49D4-97B6-2D0BFF15981AQ37882710-C8BD3DA5-2975-4F7A-AB2D-9174999ACB49Q37908891-A03F8F75-5336-48D3-B3FE-E3CF1E5828CDQ37970334-1F67226D-B711-49BE-8919-0851CC7FF617Q37989811-B1D40DDF-76F0-4E4A-A037-E486E9B28763Q38012491-74843527-F3A8-4530-95A2-057EB5C4D71BQ38098452-2194C59D-D847-4017-AB37-0A88A9FF3CAAQ38099580-E497C55E-ED2A-48EB-AFC8-68AE0389E6ADQ38758440-9FE643A7-C337-4FDF-B5CA-5256B10C5012Q38998634-EC0D751D-2708-437B-822B-155254821E5BQ42114659-9E0037B8-3E83-4DBB-9D6E-243BA01E6ED9Q42751323-9213DD3D-B36F-45AB-B77B-8A8445F779C4Q42915812-53295E20-C91C-4E81-9F85-00082898CE97Q48100807-359D8B93-6F0E-4824-AC68-58E9237117C7
P2860
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Arg389Gly-beta1-adrenergic rec ...... nic treatment with carvedilol.
@en
Arg389Gly-beta1-adrenergic rec ...... nic treatment with carvedilol.
@nl
type
label
Arg389Gly-beta1-adrenergic rec ...... nic treatment with carvedilol.
@en
Arg389Gly-beta1-adrenergic rec ...... nic treatment with carvedilol.
@nl
prefLabel
Arg389Gly-beta1-adrenergic rec ...... nic treatment with carvedilol.
@en
Arg389Gly-beta1-adrenergic rec ...... nic treatment with carvedilol.
@nl
P2093
P1476
Arg389Gly-beta1-adrenergic rec ...... onic treatment with carvedilol
@en
P2093
Andrew J Galbraith
Annalese B T Semmler
Darryl Burstow
Deborah Meyers
George Javorsky
Ian A Yang
John Atherton
Kwun M Fong
Margaret Lucas
P304
P356
10.1097/FPC.0B013E3282EF7354
P577
2007-11-01T00:00:00Z